Radiation therapy oncology group 9802: Controversy or consensus in the treatment of newly diagnosed low-grade glioma?

Seminars in Radiation Oncology

Volumn 25, Issue 3, 2015, Pages 197-202

  Laack, Nadia N ^a   Sarkaria, Jann N ^a   Buckner, Jan C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL PRACTICE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLIOMA; HIGH RISK POPULATION; HUMAN; MEDICAL LITERATURE; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; BRAIN NEOPLASMS; CONSENSUS;

BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; CONSENSUS; GLIOMA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943144495     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2015.02.004     Document Type: Review

References (30)

1. Giannini C, Burger PC, Berkey BA: Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 3:360-369, 2008
2. Hegi ME, Diserens AC, Gorlia T: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 10:997-1003, 2005
3. Jenkins RB, Blair H, Ballman KV: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 20:9852-9861, 2006
4. Sanson M, Marie Y, Paris S: Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 25:4150-4154, 2009
5. Agulnik M, Mason WP: The changing management of low-grade astrocytomas and oligodendrogliomas. Hematol Oncol Clin North Am 6:1249-1266, 2006
6. Buckner JC, Gesme Jr D, O'Fallon JR: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol 2:251-255, 2003
7. Soffietti R, Ruda R, Bradac GB: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 5:1066-1073, 1998
8. Stupp R, Mason WP, van den Bent MJ: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 10:987-996, 2005
9. Brada M, Viviers L, Abson C: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 12:1715-1721, 2003
10. van den Bent MJ, Taphoorn MJ, Brandes AA: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 13:2525-2528, 2003
11. PignattiF,van den BentM,CurranD:Prognosticfactorsforsurvivalinadult patients with cerebral low-grade glioma. J Clin Oncol 8:2076-2084, 2002
12. Schomas DA, Laack NN, Rao RD: Intracranial low-grade gliomas in adults: 30-Year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 4:437-445, 2009
13. Cairncross G, Wang M, Shaw E: Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: Long-term results of RTOG 9402. J Clin Oncol 3:337-343, 2013
14. van den Bent MJ, Brandes AA, Taphoorn MJ: Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: Long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 3:344-350, 2013
15. Lassman AB: Success at last: A molecular factor that informs treatment. Curr Oncol Rep 1:47-55, 2013
16. Karim AB, Maat B, Hatlevoll R: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 3:549-556, 1996
17. Shaw E, Arusell R, Scheithauer B: Prospective randomized trial of lowversus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 9:2267-2276, 2002
18. van den Bent MJ, Afra D, de Witte O: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial. Lancet 9490:985-990, 2005
19. Daniels TB, Brown PD, Felten SJ: Validation of EORTC prognostic factors for adults with low-grade glioma: A report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 1:218-224, 2011
20. Shaw EG, Wang M, Coons SW: Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802. J Clin Oncol 25:3065-3070, 2012
21. Buckner J, Pugh SL, Shaw EG, et al: Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in lowgrade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. Presented at the 2014 ASCO Annual Meeting, Chicago, IL, 2014
22. Clarke M, Collins R, Darby S: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 9503:2087-2106, 2005
23. Wick W, Hartmann C, Engel C: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 35:5874-5880, 2009
24. Vogelbaum MA, Berkey B, Peereboom D: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 2:167-175, 2009
25. Vogelbaum MA, Wang M, Peereboom D: RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas-Updated survival and progression free survival analysis. Neuro Oncol 14:75-76, 2012. [vi]
26. Fisher B, Jeff L, Macdonald D: A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424. Presented at the 2013 ASCO Annual Meeting, Chicago, IL, 2013
27. Claus EB, Black PM: Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: Data from the SEER program, 1973-2001. Cancer 6:1358-1363, 2006
28. Youland RS, Schomas DA, Brown PD: Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years. Neuro Oncol 8:1102-1110, 2013
29. Douw L, Klein M, Fagel SS: Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 9:810-818, 2009
30. Laack NN, Brown PD, Ivnik RJ: Cognitive function after radiotherapy for supratentorial low-grade glioma: A North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 4:1175-1183, 2005